Abbott Advances Pulsed Field Ablation Clinical Studies With Early Enrollment Completion For Volt PFA System And Launches FOCALFLEX Trial For TactiFlex Duo Ablation Catheter; Receives FDA Clearance For Advisor HD Grid X Mapping Catheter And Begins U.S. Commercial Launch
Portfolio Pulse from Benzinga Newsdesk
Abbott has completed early enrollment for its Volt PFA System clinical studies and launched the FOCALFLEX trial for the TactiFlex Duo Ablation Catheter. Additionally, Abbott received FDA clearance for the Advisor HD Grid X Mapping Catheter and has started its U.S. commercial launch.
October 10, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott has made significant progress in its medical device segment with early enrollment completion for the Volt PFA System, the launch of the FOCALFLEX trial, and FDA clearance for the Advisor HD Grid X Mapping Catheter, which is now commercially available in the U.S.
The completion of early enrollment for the Volt PFA System and the launch of the FOCALFLEX trial indicate progress in Abbott's clinical studies, which could lead to future product offerings. The FDA clearance and U.S. commercial launch of the Advisor HD Grid X Mapping Catheter are likely to positively impact Abbott's revenue and market position in the medical device sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100